Abstract
The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 221-231 |
| Number of pages | 11 |
| Journal | Postgraduate medicine |
| Volume | 103 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1998 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS